Memantin 1 A Pharma (Memantine Hydrochloride)

Memantine works as a non‑competitive antagonist of the NMDA receptor. By blocking excessive calcium entry through the receptor’s ion channel, it reduces excitotoxic neuronal damage while allowing normal synaptic transmission, thereby supporting neuronal health in Alzheimer’s disease.

The dosage of Memantin 1 A Pharma is individualized and set by the prescribing clinician based on the patient’s condition, renal function, and tolerability. Physicians typically start with a low dose and titrate upward, but exact regimens should only be provided by a qualified health professional.

Safety data for memantine during pregnancy and lactation are limited. The drug is not routinely recommended for pregnant or nursing women unless the potential benefit justifies the potential risk. Clinicians should discuss individual circumstances with the patient.

To order Memantin 1 A Pharma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas many other Alzheimer’s agents are cholinesterase inhibitors (e.g., donepezil, rivastigmine). Memantine is typically used in moderate to severe stages and may be combined with a cholinesterase inhibitor for additive benefit, while cholinesterase inhibitors are often started earlier in the disease course.

Store Memantin 1 A Pharma at ambient temperature below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed to maintain product stability.

Memantin 1 A Pharma is administered orally, with or without food. Tablets should be swallowed whole with a glass of water. The prescribing physician will determine the appropriate dosing schedule, which is usually once daily after a titration period.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, hepatic dysfunction, seizures, and emergent suicidal thoughts or behaviors. Patients should seek immediate medical attention if they experience rash, jaundice, uncontrolled seizures, or significant mood changes.

Memantin 1 A Pharma should be avoided in patients with known hypersensitivity to memantine or any excipients, those with severe renal impairment without dose adjustment, and individuals taking other NMDA antagonists that could cause additive toxicity. Clinicians must evaluate each patient’s medical history before prescribing.